



For Immediate Release

November 2, 2007

Company Name: Dainippon Sumitomo Pharma Co., Ltd.

President: Kenjiro Miyatake

Stock Exchange Listings: Tokyo, Osaka, Nagoya

Security Code number: 4506

### **Dainippon Sumitomo Pharma signs license agreement for a sedative hypnotic agent**

Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announced that it has signed an exclusive license agreement with Neurocrine Biosciences, Inc. (Head Office: San Diego, CA, President: Gary A. Lyons; hereinafter called "NBI") for *indiplon* (generic name). DSP will retain the exclusive right to develop and market *indiplon* in Japan. Under the terms of the agreement, DSP will pay NBI an upfront and milestone payments, as well as royalties on product sales in Japan.

*Indiplon* is a sedative hypnotic agent, for which NBI has worldwide development and commercialization rights. A registration program for *indiplon* has recently been completed in the U.S. for the treatment of insomnia.

An estimated 24 million people in Japan experience insomnia and the number is projected to increase under the current circumstances with social stress. Many of the patients have difficulty with initiation of sleep and a safer and more effective therapeutic agent is desired.

*Indiplon* is a potent and selective non-benzodiazepine medication targeting the GABA-A receptor. It is expected to be effective in the treatment of insomnia primarily with initiation of sleep, and to have safer profiles in terms of the reduction of adverse events, such as hang-over, amnesia and muscle relaxant, based on its shorter half-life and better receptor selectivity compared with the current short-acting insomnia drugs.

DSP has a large product portfolio in the CNS area, and expects to strengthen the lineups by this license agreement for *indiplon*. DSP will proceed with clinical development shortly with a view to launching *indiplon* in Japan as early as possible. DSP dedicates itself to contribute the treatment of insomnia and the improvement of the patients' QOL (Quality of Life).

## **About Neurocrine Biosciences, Inc.**

Company Name: Neurocrine Biosciences, Inc.

Head office: 12790 El Camino Real, San Diego, CA 92130, USA

President and CEO: Gary A. Lyons

Founded: 1992

Activity: a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders

Number of Employee: 260

Website: [http://www.neurocrine.com/home\\_int.html](http://www.neurocrine.com/home_int.html)